14 1月 2021 by admin in UncategorizedComments Dr. Han Myint Appointed as NextCure’s Chief Medical Officer
11 1月 2021 by admin in UncategorizedComments Syros Announces Strategic Priorities and Expected Milestones
07 1月 2021 by admin in UncategorizedComments 科越医药宣布获得 5350 万美元的 B+轮 1 期 融资 (first closing)，以推进 LOGIC 药物发现平台和补体靶向疗法
10 12月 2020 by admin in UncategorizedComments Crescendo Biologics Expands its Ongoing Collaboration with Takeda
07 12月 2020 by admin in UncategorizedComments Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma
01 12月 2020 by admin in UncategorizedComments Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors
05 11月 2020 by admin in UncategorizedComments Syros Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
29 10月 2020 by admin in UncategorizedComments Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New Investors
29 10月 2020 by admin in UncategorizedComments 琅铧医药与Bioprojet公司达成战略合作，获得发作性睡病治疗药物Wakix® (pitolisant)中国独家权益
24 10月 2020 by admin in UncategorizedComments Syros Presents Initial Data from Phase 1Clinical Trial of SY-5609
21 10月 2020 by admin in UncategorizedComments SAM WHITING, M.D., PH.D., joins TEMPEST as executive vice president and chief medical officer
20 10月 2020 by admin in UncategorizedComments Design Therapeutics Appoints Industry Veteran, Dr. João Siffert, as Chief Executive Officer
14 9月 2020 by admin in UncategorizedComments NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors
09 9月 2020 by admin in UncategorizedComments Syros Announces Appointment of S. Gail Eckhardt, M.D., to its Board of Directors
24 8月 2020 by admin in UncategorizedComments Arcellx Announces EvansMDS Grant Awarded for Collaboration with Johns Hopkins and University of Colorado Researchers to Support Development of Arcellx ARC-sparX Platform Candidate ACLX-002
06 8月 2020 by admin in UncategorizedComments Syros Reports Second Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
30 7月 2020 by admin in UncategorizedComments Syros to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
30 7月 2020 by admin in UncategorizedComments resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial Result
28 7月 2020 by admin in UncategorizedComments resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults
22 6月 2020 by admin in UncategorizedComments TEMPEST THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH THE COMBINATION OF TPST-1120 PLUS NIVOLUMAB IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS
28 5月 2020 by admin in UncategorizedComments resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home Residents
07 5月 2020 by admin in UncategorizedComments TEMPEST THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TPST-1495 CLINICAL STUDY: DUAL EP2/4 ANTAGONIST TARGETING SOLID TUMORS
07 5月 2020 by admin in UncategorizedComments resTORbio Provides Corporate Update and Reports First Quarter 2020 Financial Results
07 5月 2020 by admin in UncategorizedComments Syros Reports First Quarter 2020 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
05 5月 2020 by admin in UncategorizedComments Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic
29 4月 2020 by admin in UncategorizedComments resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology
